logo-loader
viewEyenovia Inc

Roth analyst bullish on Eyenovia stock after reporting 1Q results in range of expectations

A Roth Capital Partners analyst maintains a Buy rating with a $15 price target as two pivotal trials remain on track

eye
The company plans to launch studies of two drugs to treat myopia in children and glaucoma

Eyenovia Inc’s (NASDAQ:EYEN) stock remains a Buy at Roth Capital Partners after first-quarter results released Tuesday were in range with Wall Street’s expectations.

Analyst Scott Henry maintained a Buy rating with a $15 price target based in part on two pivotal trials the ophthalmic biopharmaceutical company is prepared to start in the second half of 2019, as well as the company’s planned submission of a new drug application for MicroStat in 2020.

In its earnings report, Eyenovia said the two studies are on track. The MicroProst Phase 3 program will study the treatment of chronic angle closure glaucoma, open angle glaucoma, and ocular hypertension. The study is expected to start in the fourth quarter. 

The MicroPine Phase 3 study will be aimed at reducing the progression of myopia in children, and is slated to begin in the third quarter.

“We kicked off 2019 with a number of successes that further validate our novel approach in ophthalmology that we believe will help us advance multiple programs towards Phase 3 initiations this year,” said Eyenovia CEO Sean Ianchulev in a statement.

READ: Eyenovia pushes ahead with eye drug trials as it unveils 4Q results

Eyenovia, based in New York City, reported that it ended the quarter with about $14.3 million in cash and cash equivalents. The company also recorded a net loss of about $5.9 million, or $0.50 per share, compared to a loss $3.4 million, or $0.45 per share, in the first quarter of 2018.

Henry wrote that the net loss was slightly off his $0.49 target, and  “fundamentally, we found the quarter as expected.”

Shares recently traded up 2.5% to $5.12 a piece.

Roth makes a market in shares of Eyenovia, and as such, buys and sells from customers on a principal basis.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Eyenovia Inc

Price: 2.89 USD

NASDAQ:EYEN
Market: NASDAQ
Market Cap: $57.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Thunderbird Entertainment sees strong third quarter results...

Thunderbird Entertainment (CVE: TBRD-OTC: THBRF) CEO Jennifer Twiner McCarron joined Steve Darling from Proactive Vancouver to share news the company has released their 3rd quarter financial numbers which saw a 40 per cent increase from Q-3 of last year. Twiner-McCarron talks about what led...

2 days, 6 hours ago

2 min read